Zytiga Study Supports Expansion To Early Patient Population
This article was originally published in The Pink Sheet Daily
J&J halts Phase III trial of its prostate cancer drug six months early based on the recommendation of the trial’s independent data monitoring committee.
You may also be interested in...
Data from a Phase III trial of Johnson & Johnson’s blockbuster prostate cancer drug Zytiga, which was halted for efficacy in March, were released June 2 at ASCO, but at least one expert in the field questions whether the risk to the eventual clinical results was worth it.
As expected, FDA rejected the new indication for Amgen’s bone drug Xgeva in prevention of bone metastases. But the door is still open for other therapies for castration resistant prostate cancer to target earlier stages of disease.
Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.